These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 18840241)
1. Beyond best practices: strict scrutiny as a regulatory model for race-specific medicines. Obasogie OK J Law Med Ethics; 2008; 36(3):491-7. PubMed ID: 18840241 [TBL] [Abstract][Full Text] [Related]
2. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506 [TBL] [Abstract][Full Text] [Related]
3. The case of BiDil: a policy commentary on race and genetics. Carlson RJ Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-464-8. PubMed ID: 16219648 [TBL] [Abstract][Full Text] [Related]
4. Exploiting race in drug development: BiDil's interim model of pharmacogenomics. Kahn J Soc Stud Sci; 2008 Oct; 38(5):737-58. PubMed ID: 19227819 [TBL] [Abstract][Full Text] [Related]
6. Race, money and medicines. Bloche MG J Law Med Ethics; 2006; 34(3):555-8, 480. PubMed ID: 17144179 [TBL] [Abstract][Full Text] [Related]
7. Will Precision Medicine Move Us beyond Race? Bonham VL; Callier SL; Royal CD N Engl J Med; 2016 May; 374(21):2003-5. PubMed ID: 27223144 [No Abstract] [Full Text] [Related]
8. Genes, race, and population: avoiding a collision of categories. Kahn J Am J Public Health; 2006 Nov; 96(11):1965-70. PubMed ID: 17018831 [TBL] [Abstract][Full Text] [Related]
9. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. Burroughs VJ; Maxey RW; Levy RA J Natl Med Assoc; 2002 Oct; 94(10 Suppl):1-26. PubMed ID: 12401060 [TBL] [Abstract][Full Text] [Related]
10. Genotyping the future: scientists' expectations about race/ ethnicity after BiDil. Tutton R; Smart A; Martin PA; Ashcroft R; Ellison GT J Law Med Ethics; 2008; 36(3):464-70. PubMed ID: 18840237 [TBL] [Abstract][Full Text] [Related]
12. Drugs and double binds: racial identification and pharmacogenomics in a system of binary race logic. Lynch J; Dubriwny T Health Commun; 2006; 19(1):61-73. PubMed ID: 16519593 [TBL] [Abstract][Full Text] [Related]
13. BiDil: race medicine or race marketing? Sankar P; Kahn J Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-455-63. PubMed ID: 16219647 [TBL] [Abstract][Full Text] [Related]
14. The ethical implications of stratifying by race in pharmacogenomics. Lee SS Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010 [TBL] [Abstract][Full Text] [Related]
15. Race-specific drugs: regulatory trends and public policy. Winickoff DE; Obasogie OK Trends Pharmacol Sci; 2008 Jun; 29(6):277-9. PubMed ID: 18453000 [No Abstract] [Full Text] [Related]
16. Beyond racial and ethnic analyses in clinical research: a proposed model for Institutional Review Boards. Eckstein L Food Drug Law J; 2011; 66(2):243-63, ii-iii. PubMed ID: 24505842 [TBL] [Abstract][Full Text] [Related]
17. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Ramamoorthy A; Pacanowski MA; Bull J; Zhang L Clin Pharmacol Ther; 2015 Mar; 97(3):263-73. PubMed ID: 25669658 [TBL] [Abstract][Full Text] [Related]
18. Should pharmacogenomic studies be required for new drug approval? Relling MV; Hoffman JM Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872 [TBL] [Abstract][Full Text] [Related]